Posts
Daiichi’s novel HER3 ADC has Shown To Have a Spark in HER3 NSCLC, post success in the HER3 Breast Cancer Trial
Daiichi’s novel HER3 ADC has Shown To Have a Spark in HER3 NSCLC, post success in the HER3 Breast Cancer Trial
- Get link
- Other Apps
- Get link
- Other Apps
Junshi’s domestic Toripalimab’s significant results in recurrent or metastatic HNSCC. CRL issued on Nasopharyngeal Carcinoma could prove to be a setback?
Junshi’s domestic Toripalimab’s significant results in recurrent or metastatic HNSCC. CRL issued on Nasopharyngeal Carcinoma could prove to be a setback?
- Get link
- Other Apps
Sermonix’s Lasofoxifene, a potent oral SERM, emerges as a critical player in ESR1 mutated advanced HR+ breast cancer
Sermonix’s Lasofoxifene, a potent oral SERM, emerges as a critical player in ESR1 mutated advanced HR+ breast cancer
- Get link
- Other Apps